CA2433225A1 - Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes - Google Patents
Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes Download PDFInfo
- Publication number
- CA2433225A1 CA2433225A1 CA002433225A CA2433225A CA2433225A1 CA 2433225 A1 CA2433225 A1 CA 2433225A1 CA 002433225 A CA002433225 A CA 002433225A CA 2433225 A CA2433225 A CA 2433225A CA 2433225 A1 CA2433225 A1 CA 2433225A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- binding fragment
- antigen
- complex
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des épitopes propres aux cellules cancéreuses, qui jouent un rôle important dans certains phénomènes physiologiques comme le roulement cellulaire, la métastase et l'inflammation. L'invention concerne également des procédés et des compositions thérapeutiques et diagnostiques faisant intervenir des anticorps capables de se lier avec les épitopes. Les procédés et les compositions en question peuvent s'appliquer au diagnostic et à la thérapie pour une série de maladies, à savoir par exemple: cancer, y compris la croissance tumorale et la métastase, leucémie, maladie auto-immune, et maladie inflammatoire.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25894800P | 2000-12-29 | 2000-12-29 | |
US75118100A | 2000-12-29 | 2000-12-29 | |
US09/751,181 | 2000-12-29 | ||
US60/258,948 | 2000-12-29 | ||
PCT/US2001/049442 WO2002053700A2 (fr) | 2000-12-29 | 2001-12-31 | Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2433225A1 true CA2433225A1 (fr) | 2002-07-11 |
Family
ID=26946974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002433225A Abandoned CA2433225A1 (fr) | 2000-12-29 | 2001-12-31 | Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1406930A4 (fr) |
JP (1) | JP2005503756A (fr) |
KR (1) | KR20030091953A (fr) |
CN (1) | CN100347194C (fr) |
BR (1) | BR0116764A (fr) |
CA (1) | CA2433225A1 (fr) |
CZ (1) | CZ20031982A3 (fr) |
HU (1) | HUP0700079A2 (fr) |
IL (1) | IL156689A0 (fr) |
MX (1) | MXPA03005945A (fr) |
PL (1) | PL366223A1 (fr) |
RU (1) | RU2003123101A (fr) |
WO (1) | WO2002053700A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
EP1551452A4 (fr) * | 2002-07-01 | 2006-08-30 | Savient Pharmaceuticals Inc | Compositions et procedes pour traitement therapeutique |
RU2006102571A (ru) * | 2003-06-30 | 2007-08-20 | Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) | Специфические антитела человека |
RU2006102570A (ru) * | 2003-06-30 | 2007-08-20 | Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) | Антитела и их применение |
ITMI20031714A1 (it) * | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
UY28886A1 (es) | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
WO2005110456A2 (fr) | 2004-05-11 | 2005-11-24 | Abgenomics Corporation | Epitopes induisant la mort des lymphocytes t |
DK2637672T3 (en) | 2010-11-12 | 2018-10-22 | Gentium S R L | DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD) |
US20130209449A9 (en) | 2011-06-13 | 2013-08-15 | Abgenomics Cooperatief U.A. | Anti-psgl-1 antibodies and uses thereof |
RU2627177C2 (ru) | 2012-06-22 | 2017-08-03 | Джентиум С.Р.Л. | Способ определения биологической активности дефибротида, основанный на применении эуглобулина |
WO2016013828A1 (fr) * | 2014-07-21 | 2016-01-28 | 연세대학교 산학협력단 | Mutant de domaine extracellulaire 1 de récepteur de chimiokines duffy sulfaté et utilisation associée |
EP3026122A1 (fr) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Procédé à base cellulaire pour déterminer la puissance de défibrotide |
WO2019027034A1 (fr) * | 2017-08-04 | 2019-02-07 | 公立大学法人福島県立医科大学 | Nouveau polypeptide et son application |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993011778A1 (fr) * | 1991-12-12 | 1993-06-24 | The Scripps Research Institute | Molecules anti-thrombotiques bifonctionnelles et polypetptides anti-trhombotiques |
CZ401497A3 (cs) * | 1995-06-14 | 1998-07-15 | The General Hospital Corporation | P-selektinové ligandy a příbuzné molekuly a způsoby |
DK0850243T3 (da) * | 1995-08-03 | 2004-02-02 | Univ Oklahoma | O-Glycaninhibitorer af selectinmedieret inflammation |
US5985833A (en) * | 1996-09-17 | 1999-11-16 | Wisconsin Alumni Research Foundation | Thrombin inhibitor |
US6593459B1 (en) * | 1998-06-16 | 2003-07-15 | The Board Of Regents Of The University Of Oklahoma | Synthetic glycosulfopeptides and methods of synthesis thereof |
-
2001
- 2001-12-31 KR KR10-2003-7008890A patent/KR20030091953A/ko not_active Application Discontinuation
- 2001-12-31 PL PL01366223A patent/PL366223A1/xx unknown
- 2001-12-31 CA CA002433225A patent/CA2433225A1/fr not_active Abandoned
- 2001-12-31 JP JP2002555211A patent/JP2005503756A/ja active Pending
- 2001-12-31 WO PCT/US2001/049442 patent/WO2002053700A2/fr active Application Filing
- 2001-12-31 IL IL15668901A patent/IL156689A0/xx unknown
- 2001-12-31 CN CNB018228844A patent/CN100347194C/zh not_active Expired - Fee Related
- 2001-12-31 HU HU0700079A patent/HUP0700079A2/hu unknown
- 2001-12-31 BR BRPI0116764-2A patent/BR0116764A/pt not_active IP Right Cessation
- 2001-12-31 EP EP01994330A patent/EP1406930A4/fr not_active Withdrawn
- 2001-12-31 RU RU2003123101/13A patent/RU2003123101A/ru not_active Application Discontinuation
- 2001-12-31 CZ CZ20031982A patent/CZ20031982A3/cs unknown
- 2001-12-31 MX MXPA03005945A patent/MXPA03005945A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA03005945A (es) | 2004-10-15 |
IL156689A0 (en) | 2004-01-04 |
CN1649900A (zh) | 2005-08-03 |
JP2005503756A (ja) | 2005-02-10 |
WO2002053700A2 (fr) | 2002-07-11 |
EP1406930A4 (fr) | 2007-01-10 |
EP1406930A2 (fr) | 2004-04-14 |
WO2002053700A3 (fr) | 2004-02-12 |
BR0116764A (pt) | 2007-01-09 |
HUP0700079A2 (en) | 2007-05-02 |
PL366223A1 (en) | 2005-01-24 |
RU2003123101A (ru) | 2005-03-10 |
CN100347194C (zh) | 2007-11-07 |
KR20030091953A (ko) | 2003-12-03 |
CZ20031982A3 (cs) | 2004-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040002450A1 (en) | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
US20040001822A1 (en) | Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
US20040001839A1 (en) | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
US20070149768A1 (en) | Specific human antibodies for selective cancer therapy | |
US20090220486A1 (en) | Antibodies and uses thereof | |
CA2433225A1 (fr) | Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes | |
AU2002246737B2 (en) | Specific human antibodies for selective cancer therapy | |
JP2005503756A5 (fr) | ||
AU2002246737A1 (en) | Specific human antibodies for selective cancer therapy | |
US20040202665A1 (en) | Compositions and methods for therapeutic treatment | |
CA2491363A1 (fr) | Anticorps et leurs applications | |
US20080274100A1 (en) | Antibodies and uses thereof | |
AU2003279657A1 (en) | Compositions and methods for therapeutic treatment | |
EP1649001A2 (fr) | Anticorps et utilisations de ceux-ci | |
CA2531283A1 (fr) | Anticorps humains specifiques | |
US20040208877A1 (en) | Antibodies and uses thereof | |
AU2002246738A1 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |